BIOTECHNOLOGY

Novotech now has over 20 significant Partnerships with some of the leading medical institutions in the region.

This will provide a significant increase in its manufacturing footprint, resulting in Europe’s largest capacity for rapid test manufacturing. This news comes weeks after the UK Government announced Abingdon Health as one of the leading members of the UK Rapid Test Consortium

Validation of its CE-IVD UltraGene® Combo2Screen SARS-CoV-2 qPCR assay to be used straight from non-invasive fluid saliva samples and allowing for broad population screening.

Since formalizing the partnership in May, the duo has kicked off projects with 24 states, with two, Illinois and Delaware, now fully live.

“We are delighted to present a method to stratify patients responding to immunotherapy by a single tube of blood collected after completion of CRT,” said Dr. Cha-Mei Tang, CEO of Creatv. “Early identification of patients that do not respond to immunotherapy will reduce unnecessary patient suffering from ineffective and costly treatment, allowing patients to proceed to alternative therapies.” Currently, no other blood test can predict immunotherapy treatment response for lung cancer.

This agreement is an outcome of an ongoing collaboration between Fibralign and Terumo where the two companies have agreed to partner in efforts to commercialize BioBridge in Japan.

SARS-Hunter gives the possibility to hospitals to isolate the antibodies from plasma to be given as therapy and increases the chances of success of treatment, while reducing the side effects of plasma therapy given today.

The paper, entitled “Late pregnancy screening for preeclampsia with a urinary point-of-care test for misfolded proteins”, was written by collaborators from China Medical University's Shengjing Hospital and Columbia University Medical Center in New York and demonstrates the ability of the test to detect preeclampsia at a high level of accuracy in women admitted to the hospital for any reason. The findings included over 1,500 women and were published in the peer-reviewed journal PLOS One.

The SOLIUS technology stimulates the production of vitamin D in the skin using a narrow spectrum of ultraviolet B (UVB) light.